AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR

气道灌注辅助液体呼吸机

• 批准号: 6404857
• 负责人: JAMES Courtney PARKER
• 金额: $ 24.98万
• 依托单位: MALLARD MEDICAL CO., INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2003-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6404857
• 关键词: cystic fibrosis; fluid; fluosol; histology; laboratory rabbit; perfusion; respirators; respiratory airway clearance; respiratory airway volume; respiratory disorder chemotherapy; respiratory insufficiency /failure; swine; technology /technique development

DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid ventilator with enhanced capabilities for gas exchange and exudates clearance from the lungs. This system has potential application to rescue of patients in acute respiratory failure and treatment of cystic fibrosis. The system employs a continuous isovolumetric perfusion (bias flow) of oxygenated PFC through one lumen of a double lumen endotracheal catheter that is superimposed on tidal liquid ventilation (liv). Phase I studies in newborn piglets indicate that bias flow significantly improved blood gases and increased the clearance of a five percent albumin solution from the lung by over 3-fold. During Phase II we propose to finalize the prototype design and control system software for ventilatory parameters and a feedback control of lung liquid volume based on measurements of end-expiratory stop-flow pressures. High performance pulseless pumps, an oxygenator and vapor recovery system will be included as well as protective algorithms and relief valves to limit airway pressure excursions. Phase II experimental studies in piglets and rabbits will examine novel applications of TLV with bias flow for sustaining arterial blood gases during oleic acid lung injury, increasing the clearance rate of five percent albumin solution and mucus-like gels from the lung, and enhancing the homogeneity of gene expression for a reporter gene introduced during TLV. We will also apply for an Investigational Device Exemption (IDE) from the Food and Drug Administration during Phase II to distribute ventilator prototypes to research institutions. PROPOSED COMMERCIAL APPLICATION: This liquid ventilator will be used in infant and adult intensive care units to treat end-stage respiratory failure as a lower cost alternative to extracorporeal oxygenation. Other applications include continuous intrapulmonary administration of drugs and anesthetics and clearance of material from the lungs.

描述（由申请人提供）：我们已经开发并获得专利（美国专利号 No.5，706，830）的新型闭路全氟化碳（PFC）液体 具有增强的气体交换和渗出物清除能力的呼吸机 从肺部。该系统具有潜在的应用，以抢救病人， 急性呼吸衰竭和囊性纤维化的治疗。该系统采用 氧合PFC的连续等容灌注（偏流）通过一个 双腔气管内导管的腔，其叠加在潮气上 液体通气（liv）。新生仔猪的I期研究表明， 流动显着改善血液气体，并增加了五个清除 白蛋白溶液从肺中的百分比超过3倍。在第二阶段，我们 建议完成原型设计和控制系统软件， 肺容量的反馈控制 呼气末停止流动压力的测量。高性能无脉 泵，氧合器和蒸汽回收系统将包括以及 保护算法和减压阀，以限制气道压力偏移。 在仔猪和家兔中进行的II期实验研究将检查新的 TLV与偏流在维持动脉血气中的应用 油酸肺损伤，增加百分之五的白蛋白清除率 溶液和粘液样凝胶从肺，并提高均匀性， 在TLV期间引入的报告基因的基因表达。我们还将应用 申请食品药品监督管理局的试验用器械豁免（IDE） II期管理，将呼吸机原型分发给研究 机构职能体系 拟定商业应用： 这种液体呼吸机将用于婴儿和成人重症监护病房，以治疗终末期呼吸衰竭，作为体外氧合的低成本替代方案。 其他应用包括药物和麻醉剂的连续肺内给药以及从肺部清除物质。